etanercept

etanercept is a biopharmaceutical drug that interferes with tumor necrosis factor (TNF; a soluble inflammatory cytokine) and is used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis. It is marketed by Pfizer under the trade name Enbrel and is also used to treat ankylosing spondylitis and juvenile idiopathic arthritis. The development of etanercept is attributed to the work of Roy Vagelos and his team at Regeneron Pharmaceuticals, in collaboration with researchers at Immunex Corporation and University of California, San Francisco.

Introduction

Etanercept is a fusion protein that combines the extracellular ligand-binding portion of the human tumor necrosis factor receptor with the Fc portion of IgG1, allowing it to bind to tumor necrosis factor-alpha (TNF-alpha) and prevent it from interacting with cell surface TNF receptors, thereby reducing inflammation and immune system activity. This mechanism is similar to that of other TNF inhibitors, such as adalimumab and infliximab, which are used to treat similar conditions, including Crohn's disease and ulcerative colitis, at institutions like Johns Hopkins University and University of Oxford. Researchers at Harvard University and Stanford University have also investigated the use of etanercept in treating other conditions, such as multiple sclerosis and lupus erythematosus, in collaboration with organizations like the National Institutes of Health and the Arthritis Foundation.

Mechanism_of_action

The mechanism of action of etanercept involves binding to TNF-alpha, a pro-inflammatory cytokine that plays a key role in the regulation of immune cells, such as T cells and macrophages, which are involved in the pathogenesis of various autoimmune diseases, including rheumatoid arthritis and psoriasis. By preventing TNF-alpha from interacting with its receptors on the surface of cells, etanercept reduces the production of other pro-inflammatory cytokines, such as interleukin-1 and interleukin-6, which are produced by cells like dendritic cells and fibroblasts at institutions like University of California, Los Angeles and Columbia University. This reduction in inflammation and immune system activity leads to a decrease in the symptoms of autoimmune diseases, such as joint pain and swelling, which are commonly treated by specialists at Mayo Clinic and Massachusetts General Hospital.

Medical_uses

Etanercept is used to treat a variety of autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and juvenile idiopathic arthritis. It is also used to treat other conditions, such as polyarticular juvenile idiopathic arthritis and psoriatic arthritis with axial involvement, which are often managed by specialists at University of Pennsylvania and Duke University. The use of etanercept has been investigated in other conditions, such as multiple sclerosis and lupus erythematosus, in collaboration with researchers at University of California, San Diego and Yale University, and organizations like the National Multiple Sclerosis Society and the Lupus Research Alliance.

Side_effects

The most common side effects of etanercept include injection site reactions, such as redness, swelling, and pain, which are similar to those experienced with other biologic therapies, such as rituximab and abatacept, used to treat conditions like non-Hodgkin's lymphoma and rheumatoid arthritis at institutions like MD Anderson Cancer Center and University of Chicago. Other side effects of etanercept include upper respiratory tract infections, such as sinusitis and bronchitis, which are commonly treated by specialists at Cleveland Clinic and University of Washington. Rare but serious side effects of etanercept include sepsis, tuberculosis, and demylination, which are often managed by experts at Centers for Disease Control and Prevention and World Health Organization.

History

Etanercept was first approved by the US Food and Drug Administration (FDA) in 1998 for the treatment of rheumatoid arthritis and was later approved for the treatment of psoriatic arthritis and plaque psoriasis. The development of etanercept is attributed to the work of researchers at Immunex Corporation, which was acquired by Amgen in 2002, and Regeneron Pharmaceuticals, which has also developed other biologic therapies, such as aflibercept and dupilumab, used to treat conditions like age-related macular degeneration and atopic dermatitis at institutions like University of Michigan and University of Texas.

Pharmacology

Etanercept is administered via subcutaneous injection, typically once or twice a week, and has a half-life of approximately 70-100 hours, which allows for sustained therapeutic levels of the drug in the body, similar to other biologic therapies, such as adalimumab and infliximab, used to treat conditions like Crohn's disease and ulcerative colitis at institutions like University of California, Berkeley and New York University. The pharmacokinetics of etanercept have been studied in various populations, including patients with renal impairment and hepatic impairment, which are often managed by specialists at National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Environmental Health Sciences. Researchers at University of Illinois and University of Wisconsin have also investigated the use of etanercept in combination with other therapies, such as methotrexate and cyclosporine, to treat various autoimmune diseases. Category:Biologic drugs